These results indicated that Bcl-xL is responsible for the TRAIL resistance of AsPC-1 and Panc-1 cells and that inhibition of this anti-apoptotic protein can effectively sensitize TRAIL-resistant pancreatic cancer cells to TRAIL. Here, BCL2L1 is linked to pancreatic neoplasm.